<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012246458
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pentix
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GABAPENTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        39.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Pentix<sup>&reg;</sup></strong> belongs to a group of medicines used to treat epilepsy and peripheral neuropathic pain (long lasting pain caused by damage to the nerves).</p><p>The active substance in <strong>Pentix<sup>&reg;</sup></strong> is gabapentin.</p><p><strong>Pentix<sup>&reg;</sup> is used to treat </strong></p><p>Various forms of epilepsy (seizures that are initially limited to certain parts of the brain, whether the seizure spreads to other parts of the brain or not). The doctor treating you or your child 6 years of age and older will prescribe <strong>Pentix<sup>&reg;</sup></strong> to help treat epilepsy when the current treatment is not fully controlling the condition. You or your child 6 years of age and older should take <strong>Pentix<sup>&reg; </sup></strong>in addition to the current treatment unless told otherwise. <strong>Pentix<sup>&reg; </sup></strong>can also be used on its own to treat adults and children over 12 years of age.</p><p>Peripheral neuropathic pain (long lasting pain caused by damage to the nerves). A variety of different diseases can cause peripheral neuropathic pain (primarily occurring in the legs and/or arms), such as diabetes or shingles. Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles etc.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pentix<sup>&reg;</sup>:</strong></p><p>If you are allergic (hypersensitive) to gabapentin or any of the other ingredients of this medicine.</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor or pharmacist before taking Pentix<sup>&reg;</sup> </strong></p><p>If you suffer from kidney problems your doctor may prescribe a different dosing schedule.</p><p>If you are on haemodialysis (to remove waste products because of kidney failure), tell your doctor if you develop muscle pain and/or weakness.</p><p>If you develop signs such as persistent stomach pain, feeling sick and being sick contact your doctor immediately as these may be symptoms of acute pancreatitis (an inflamed pancreas).</p><p>If you have nervous system disorders, respiratory disorders, or you are more than 65 years old, your doctor may prescribe you a different dosing regimen.</p><p>&nbsp;</p><p>Cases of abuse and dependence have been reported for gabapentin from the post-marketing experience. Talk to your doctor if you have a history of abuse or dependence.</p><p>A small number of people being treated with anti-epileptics such as gabapentin have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p><strong>Important information about potentially serious reactions </strong></p><p>A small number of people taking <strong>Pentix<sup>&reg; </sup></strong>get an allergic reaction or potentially serious skin reaction, which may develop into more serious problems if they are not treated. You need to know the symptoms to look out for while you are taking <strong>Pentix<sup>&reg;</sup></strong>.</p><p>Muscle weakness, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems. You may also experience discoloration of your urine, and a change in blood test results (notably blood creatine phosphokinase increased). If you experience any of these signs or symptoms, please contact your doctor immediately.</p><p><strong>Other medicines and Pentix<sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor (or pharmacist) if you are taking or have been recently taking any medicines for convulsions, sleeping disorders, depression, anxiety, or any other neurological or psychiatric problems.</p><p><strong>Medicines containing opioids such as morphine </strong></p><p>If you are taking any medicines containing opioids (such as morphine), please tell your doctor or pharmacist as opioids may increase the effect of <strong>Pentix<sup>&reg;</sup></strong>. In addition, combination of <strong>Pentix<sup>&reg; </sup></strong>with opioids may cause sleepiness, sedation, decrease in breathing, or death.&nbsp;</p><p><strong>Antacids for indigestion </strong></p><p>If <strong>Pentix<sup>&reg; </sup></strong>and antacids containing aluminium and magnesium are taken at the same time, absorption of <strong>Pentix<sup>&reg; </sup></strong>from the stomach may be reduced. It is therefore recommended that <strong>Pentix<sup>&reg; </sup></strong>is taken at the earliest two hours after taking an antacid.</p><p><strong>Pentix<sup>&reg;</sup></strong></p><p>Is not expected to interact with other antiepileptic drugs or the oral contraceptive pill.</p><p>May interfere with some laboratory tests, if you require a urine test tell your doctor or hospital what you are taking.</p><p><strong>Pentix<sup>&reg; </sup>with food </strong></p><p><strong>Pentix<sup>&reg; </sup></strong>can be taken with or without food.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Pregnancy </strong></p><p><strong>Pentix<sup>&reg; </sup></strong>should not be taken during pregnancy, unless you are told otherwise by your doctor. Effective contraception must be used by women of child-bearing potential.</p><p>There have been no studies specifically looking at the use of gabapentin in pregnant women, but other medications used to treat seizures have reported an increased risk of harm to the developing baby, particularly when more than one seizure medication is taken at the same time. Therefore, whenever possible, you should try to take only one seizure medication during pregnancy and only under the advice of your doctor.</p><p>Contact your doctor immediately if you become pregnant, think you might be pregnant or are planning to become pregnant while taking <strong>Pentix<sup>&reg;</sup></strong>. Do not suddenly discontinue taking this medicine as this may lead to a breakthrough seizure, which could have serious consequences for you and your baby.</p><p><strong>Breast-feeding </strong></p><p>Gabapentin, the active substance of <strong>Pentix<sup>&reg;</sup></strong>, is passed on through human milk. Because the effect on the baby is unknown, it is not recommended to breast-feed while using <strong>Pentix<sup>&reg;</sup></strong>.</p><p><strong>Fertility </strong></p><p>There is no effect on fertility in animal studies.</p><p><strong>Driving and using machines </strong></p><p><strong>Pentix<sup>&reg; </sup></strong>may produce dizziness, drowsiness and tiredness. You should not drive, operate complex machinery or take part in other potentially hazardous activities until you know whether this medication affects your ability to perform these activities.</p><p><strong>Pentix<sup>&reg;</sup> contains lactose </strong></p><p><strong>Pentix<sup>&reg; </sup></strong>capsules contain lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will determine what dose is appropriate for you.</p><p><strong>Epilepsy, the recommended dose is </strong></p><p><strong>Adults and adolescents </strong></p><p>Take the number of capsules as instructed. Your doctor will usually build up your dose gradually. The starting dose will generally be between 300 mg and 900 mg each day. Thereafter, the dose may be increased as instructed by your doctor, up to a maximum of 3600 mg each day and your doctor will tell you to take this in 3 separate doses, i.e. once in the morning, once in the afternoon and once in the evening.</p><p><strong>Children aged 6 years and above </strong></p><p>The dose to be given to your child will be decided by your doctor as it is calculated against your child&rsquo;s weight. The treatment is started with a low initial dose which is gradually increased over a period of approximately 3 days. The usual dose to control epilepsy is 25-35 mg per kg per day. It is usually given in 3 separate doses, by taking the capsule(s) each day, usually once in the morning, once in the afternoon and once in the evening.</p><p><strong>Pentix<sup>&reg; </sup></strong>is not recommended for use in children below 6 years of age.</p><p><strong>Peripheral Neuropathic Pain, the recommended dose is </strong></p><p><strong>Adults </strong></p><p>Take the number of capsules as instructed by your doctor. Your doctor will usually build up your dose gradually. The starting dose will generally be between 300 mg and 900 mg each day. Thereafter, the dose may be increased as instructed by your doctor up to a maximum of 3600 mg each day and your doctor will tell you to take this in 3 separate doses, i.e. once in the morning, once in the afternoon and once in the evening.</p><p><strong>If you have kidney problems or are receiving haemodialysis </strong></p><p>Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys or are undergoing haemodialysis.</p><p><strong>If you are an elderly patient (over 65 years of age) </strong></p><p>You should take the normal dose of <strong>Pentix<sup>&reg; </sup></strong>unless you have problems with your kidneys. Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.</p><p>If you have the impression that the effect of <strong>Pentix<sup>&reg; </sup></strong>is too strong or too weak, talk to your doctor or pharmacist as soon as possible.</p><p><strong>Method of administration </strong></p><p><strong>Pentix<sup>&reg; </sup></strong>is for oral use. Always swallow the capsules with plenty of water.</p><p>Continue taking <strong>Pentix<sup>&reg; </sup></strong>until your doctor tells you to stop.</p><p><strong>If you take more Pentix<sup>&reg; </sup>than you should </strong></p><p>Higher than recommended doses may result in an increase in side effects including loss of consciousness, dizziness, double vision, slurred speech, drowsiness and diarrhea. Call your doctor or go to the nearest hospital emergency unit immediately if you take more <strong>Pentix<sup>&reg; </sup></strong>than your doctor prescribed. Take along any capsules that you have not taken, together with the container and the label so that the hospital can easily tell what medicine you have taken.</p><p><strong>If you forget to take Pentix<sup>&reg;</sup></strong></p><p>If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Pentix<sup>&reg;</sup></strong></p><p>Do not stop taking <strong>Pentix<sup>&reg; </sup></strong>unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week. If you stop taking <strong>Pentix<sup>&reg; </sup></strong>suddenly or before your doctor tells you, there is an increased risk of seizures.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Contact your doctor immediately if you experience any of the following symptoms after taking this medicine as they can be serious: </strong></p><p>Severe skin reactions that require immediate attention, swelling of the lips and face, skin rash and redness, and/or hair loss (these may be symptoms of a serious allergic reaction)</p><p>Persistent stomach pain, feeling sick and being sick as these may be symptoms of acute pancreatitis (an inflamed pancreas)</p><p>Breathing problems, which if severe you may need emergency and intensive care to continue breathing normally</p><p>Gabapentin may cause a serious or life-threatening allergic reaction that may affect your skin or other parts of your body such as your liver or blood cells. You may or may not have rash when you get this type of reaction. It may cause you to be hospitalized or to stop gabapentin. Call your doctor right away if you have any of the following symptoms:</p><p>- Skin rash.</p><p>- Hives.</p><p>- Fever.</p><p>- Swollen glands that do not go away.</p><p>- Swelling of your lip and tongue.</p><p>- Yellowing of your skin or of the whites of the eyes.</p><p>- Unusual bruising or bleeding.</p><p>- Severe fatigue or weakness.</p><p>- Unexpected muscle pain.</p><p>- Frequent infections.</p><p><strong>These symptoms may be the first signs of a serious reaction. A doctor should examine you to decide if you should continue taking gabapentin. </strong></p><p>If you are on haemodialysis, tell your doctor if you develop muscle pain and/or weakness.</p><p><strong>Other side effects include: </strong></p><p><strong>Very common: (may affect more than 1 in 10 people) </strong></p><p>Viral infection.</p><p>Feeling drowsy, dizziness, lack of coordination.</p><p>Feeling tired, fever.</p><p><strong>Common: (may affect up to 1 in 10 people) </strong></p><p>Pneumonia, respiratory infections, urinary tract infection, inflammation of the ear or other infections.</p><p>Low white blood cell counts.</p><p>Anorexia, increased appetite.</p><p>Anger towards others, confusion, mood changes, depression, anxiety, nervousness, difficulty with thinking.</p><p>Convulsions, jerky movements, difficulty with speaking, loss of memory, tremor, difficulty sleeping, headache, sensitive skin, decreased sensation (numbness), difficulty with coordination, unusual eye movement, increased, decreased or absent reflexes.</p><p>Blurred vision, double vision.</p><p>Vertigo.</p><p>High blood pressure, flushing or dilation of blood vessels.</p><p>Difficulty breathing, bronchitis, sore throat, cough, dry nose.</p><p>Vomiting (being sick), nausea (feeling sick), problems with teeth, inflamed gums, diarrhea, stomach pain, indigestion, constipation, dry mouth or throat, flatulence.</p><p>Facial swelling, bruises, rash, itch, acne.</p><p>Joint pain, muscle pain, back pain, twitching.</p><p>Difficulties with erection (impotence).</p><p>Swelling in the legs and arms, difficulty with walking, weakness, pain, feeling unwell, flu-like symptoms.</p><p>Decrease in white blood cells, increase in weight.</p><p>Accidental injury, fracture, abrasion.</p><p>Additionally in clinical studies in children, aggressive behaviour and jerky movements were reported commonly.</p><p><strong>Uncommon: (may affect up to 1 in 100 people) </strong></p><p>Agitation (a state of chronic restlessness and unintentional and purposeless motions).</p><p>Allergic reaction such as hives.</p><p>Decreased movement.</p><p>Racing heartbeat.</p><p>Difficulty swallowing.</p><p>Swelling that may involve the face, trunk and limbs.</p><p>Abnormal blood test results suggesting problems with the liver.</p><p>Mental impairment.</p><p>Fall.</p><p>Increase in blood glucose levels (most often observed in patients with diabetes).</p><p><strong>Rare: (may affect up to 1 in 1,000 people) </strong></p><p>Decrease in blood glucose levels (most often observed in patients with diabetes).</p><p>Loss of consciousness.</p><p>Trouble breathing, shallow breaths (respiratory depression).</p><p><strong>After marketing Gabapentin<sup> </sup>the following side effects have been reported: </strong></p><p>Decreased platelets (blood clotting cells).</p><p>Suicidal thoughts, hallucinations.</p><p>Problems with abnormal movements such as writhing, jerking movements and stiffness.</p><p>Ringing in the ears.</p><p>A group of side effects that could include swollen lymph nodes (isolated small raised lumps under the skin), fever, rash, and inflammation of liver occurring together.</p><p>Yellowing of the skin and eyes (jaundice), inflammation of the liver.</p><p>Acute kidney failure, incontinence.</p><p>Increased breast tissue, breast enlargement.</p><p>Adverse events following the abrupt discontinuation of gabapentin (anxiety, difficulty sleeping, feeling sick, pain, sweating, chest pain).</p><p>Breakdown of muscle fibers (rhabdomyolysis).</p><p>Change in blood test results (creatine phosphokinase increased).</p><p>Problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation.</p><p>Low blood sodium level.</p><p>Anaphylaxis (serious, potentially life threatening allergic reaction including difficulty breathing, swelling of the lips, throat, and tongue, and hypotension requiring emergency treatment).</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Pentix<sup>&reg;</sup> </strong>Capsules after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Pentix<sup>&reg;</sup> </strong>Capsules: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Pentix<sup>&reg;</sup> Capsules contain</strong></p><p>The active substance is Gabapentin.</p><p>The other ingredients are lactose monohydrate, Maize starch, Talc, magnesium stearate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pentix® 300mg capsules: Size zero, hard gelatin capsule, with beige color body printed with “CAP02” and brownish orange color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.
pack size: 30 Hard Getain Capsules (10 capsules/blister, 3 blisters/pack).

Pentix® 400mg capsules: Size zero elongated, hard gelatin capsule, with Ivory opaque color body printed with “CAP03” and blue opaque color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.
pack size: 30 Hard Getain Capsules (10 capsules/blister, 3 blisters/pack).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Med City Pharma-KSA.</p><p>Tel: 00966920003288</p><p>Fax: 00966126358138</p><p>Mobile: 00966555786968</p><p>P.O .Box: 42512 - Jeddah 21551</p><p>E-mail: MD.admin@Axantia.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2024                             
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>إلى مجموعة الأدوية التي تستعمل لعلاج الصرع و الألم الناتج عن الاعتلال العصبي الطرفي (الألم طويل الأمد الناتج عن تلف الأعصاب).</p><p dir="RTL">المادة الفعالة في <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>هي جابابنتين.</p><p dir="RTL"><strong>يستعمل</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">الأشكال المختلفة من الصرع (النوبات التي تكون محدودة بشكل مبدئي بأجزاء معينة من الدماغ، سواء انتشرت النوبات إلى أجزاء أخرى من الدماغ أم لم تنتشر). سيقوم الطبيب بوصف <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>لك أو لطفلك الذي يبلغ من العمر 6 أعوام أو أكبر للمساعدة في علاج الصرع لديك عندما يكون علاجك الحالي غير كافي للسيطرة بشكل كامل على حالتك. يجب عليك أنت أو طفلك الذي يبلغ من العمر 6 أعوام أو أكبر تناول<sup> </sup><strong>بينتكس</strong><strong><sup>&reg; </sup></strong>بالإضافة لعلاجك الحالي ما لم يخبرك الطبيب غير ذلك. من الممكن أيضا استعمال <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>لوحده لعلاج البالغين والأطفال الذين تزيد أعمارهم عن 12 عام.</p><p dir="RTL">الألم الناتج عن الاعتلال العصبي الطرفي (الألم طويل الأمد الناتج عن تلف الأعصاب). قد تسبب العديد من الأمراض المختلفة الألم الناتج عن الاعتلال العصبي الطرفي (بشكل رئيسي الذي يحدث في الساقين و/أو الذراعين)، مثل داء السكري أو الحلأ النطاقي.من الممكن وصف الشعور بالألم كارتفاع في درجة حرارة الجسم، حرقة، خفقان، أو كالألم الناتج عن إطلاق النار، والطعن بآلة حادة، ألم حاد، تشنج، ألم مستمر، تنميل، و الإحساس بوخز خفيف إلخ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب</strong><strong> </strong><strong>عدم</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من تحسس (فرط التحسس) لجابابنتين أو لأي مكونات أخرى في هذا الدواء.</p><p dir="RTL"><strong>الاحتياطات</strong><strong> </strong><strong>والمحاذير</strong><strong>:</strong></p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong><strong>: </strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى حيث قد يصف لك الطبيب نظام جرعة مختلف.</p><p dir="RTL">إذا كنت تخضع للديلزة الدموية (للتخلص من الفضلات بسبب قصور وظيفة الكلى)، أخبر طبيبك إذا حصل لديك ألم و/أو ضعف في العضلات.</p><p dir="RTL">إذا حصل لديك علامات مثل ألم مستمر في المعدة، الشعور بالغثيان و قيء، اتصل مع طبيبك فورا حيث قد تكون هذه أعراض لالتهاب حاد ف البنكرياس.</p><p dir="RTL">إذا كنت تعاني من اضطرابات في الجهاز العصبي، اضطرابات تنفسية، أو إذا كان عمرك يزيد ن 65 عاما، قد يقوم الطبيب بوصف نظام جرعة مختلف لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تسجيل حالات سوء استعمال جابابنتين خلال تجربة ما بعد التسويق. تحدث مع طبيبك إذا كان لديك تاريخ من سوء استعمال الأدوية.</p><p dir="RTL">حصل لدى عدد قليل من المرضى الذين يتم علاجهم بمضادات الصرع مثل جابابنتين تفكير بإيذاء أو قتل أنفسهم. إذا حصل لديك هذه الأفكار في أي وقت. اتصل مع طبيبك فورا.</p><p dir="RTL"><strong>معلومات</strong><strong> </strong><strong>مهمة</strong><strong> </strong><strong>حول</strong><strong> </strong><strong>تفاعلات</strong><strong> </strong><strong>خطيرة</strong><strong> </strong><strong>محتملة</strong></p><p dir="RTL">حصل لدى عدد قليل من الأشخاص الذين يتناولون <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>تفاعل تحسس أو تفاعل خطير محتمل في الجلد، الذي قد يتطور إلى مشاكل أكثر خطورة إذا لم يعالج. تحتاج لمعرفة هذه الأعراض لتكن حذرا خلال فترة تناولك <strong>بينتكس</strong><strong><sup>&reg;</sup></strong>.</p><p dir="RTL">ضعف العضلات، الشعور بالتعب أو الألم وخاصة، إذا شعرت بنفس الوقت بأنك لست على ما يرام أو ارتفاع في درجة حرارة الجسم وقد تكون هذه الأعراض ناتجة عن تحلل غير طبيعي في العضلات والذي قد يكون مهدد للحياة و يؤدي إلى مشاكل في الكلى. قد تعاني أيضا من تغير لون البول، وتغير في نتائج فحوصات الدم (زيادة مستوى كرياتين فوسفوكاينيز بشكل ملحوظ). إذا حصل لديك أي من هذه العلامات أو الأعراض، الرجاء الاتصال مع طبيبك فورا.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول ، تناولت مؤخرا أو من الممكن أن تتناول أي أدوية أخرى. بشكل خاص، أخبر طبيبك (أو الصيدلي) إذا كنت تتناول ، تناولت مؤخرا أي أدوية لعلاج التشنجات، اضطرابات النوم، الاكتئاب، القلق، أو أي مشاكل عصبية أو نفسية.</p><p dir="RTL"><strong>أدوية</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>المواد</strong><strong> </strong><strong>الأفيونية</strong><strong> </strong><strong>مثل</strong><strong> </strong><strong>المورفين</strong></p><p dir="RTL">إذا كنت تتناول أدوية تحتوي على المواد الأفيونية (مثل المورفين)، الرجاء إخبار طبيبك أو الصيدلي حيث قد تزيد المواد الأفيونية من تأثير <strong>بينتكس</strong><strong><sup>&reg;</sup></strong>.<sup> </sup>بالإضافة لذلك، قد يسبب تناول <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>بشكل متزامن مع المواد الأفيونية الشعور بالنعاس، سكون، انخفاض القدرة على التنفس، أو الوفاة.</p><p dir="RTL"><strong>مضادات</strong><strong> </strong><strong>الحموضة</strong></p><p dir="RTL">إذا تم تناول <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup>في<strong> </strong>نفس الوقت مع مضادات الحموضة المحتوية على الألومنيوم و المغنيسيوم، قد يقل امتصاص<sup> </sup><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup>من المعدة. لذلك يوصى بتناول<sup> </sup><strong>بينتكس</strong><strong><sup>&reg;</sup></strong> بعد ساعتين من تناول مضادات الحموضة.</p><p dir="RTL"><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup></p><p dir="RTL">من غير المتوقع أن يتفاعل مع الأدوية الأخرى المضادة للصرع أو أقراص منع الحمل التي يتم تناولها عن طريق الفم.</p><p dir="RTL">قد يؤثر على بعض الفحوصات المخبرية، إذا كنت بحاجة للقيام بفحص بول، أخبر طبيبك أو المستشفى عن الأدوية التي تتناولها.</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong></p><p dir="RTL">من الممكن تناول <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup>مع أو بدون تناول الطعام.</p><p dir="RTL"><strong>الحمل،</strong><strong> </strong><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong><strong> </strong><strong>و</strong><strong> </strong><strong>الخصوبة</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعة، تعتقدين بأنك حاملا أو تخططين للحمل، إستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب عدم تناول <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>خلال فترة الحمل ما لم يخبرك الطبيب بغير ذلك. يجب استعمال موانع حمل فعالة من قبل النساء في سن الإنجاب.</p><p dir="RTL">لا يوجد دراسات تتعلق بشكل خاص باستعمال جابابنتين للنساء الحوامل، لكن تم تسجيل زيادة خطر تعرض الجنين للخطر عند استعمال أدوية أخرى تستعمل لعلاج نوبات الصرع، خصوصا عند استعمال أكثر من دواء لعلاج نوبات الصرع في نفس الوقت. لذلك، إذا أمكن، يجب محاولة تناول دواء واحد لعلاج نوبات الصرع خلال فترة الحمل وفقط تحت إشراف الطبيب.</p><p dir="RTL">أخبري طبيبك على الفور إذا حصل الحمل، أو كنت تعتقدين بأنك حامل أو تخططين للحمل خلال فترة تناول&nbsp; <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>.<strong> </strong>لا تتوقف عن تناول هذا الدواء فجأة حيث قد يؤدي ذلك إلى ازدياد حالة نوبات الصرع سوءا، التي قد ينتج عنها عواقب خطيرة لك ولطفلك.</p><p dir="RTL"><strong>الرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">يفرز جابابنتين وهو المادة الفعالة في<strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup>في حليب الثدي. لا يوصى بالرضاعة الطبيعية خلال فترة تناول <strong>بينتكس</strong><strong><sup>&reg; </sup></strong>لأن تأثيره على الرضيع غير معروف.</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">لا يوجد تأثير على الخصوبة في الدراسات على الحيوانات.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد يسبب <strong>بينتكس</strong><strong><sup>&reg;</sup></strong> الشعور بالدوار، النعاس والتعب. يجب تجنب القيادة، تشغيل الآلات المعقدة أو المشاركة في أي نشاطات أخرى من المحتمل أن تكون خطيرة إلى أن تتأكد من تأثير هذا الدواء على قدرتك على القيام بهذه الأنشطة.</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong></p><p dir="RTL">تحتوي كبسولات <strong>بينتكس</strong><strong><sup>&reg;</sup></strong> على اللاكتوز (أحد أنواع السكريات). إذا أخبرت من قبل الطبيب أنك لا تستطيع تحمل بعض أنواع السكريات، اتصل مع طبيبك قبل تناول هذاالدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك أو الصيدلي. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL">سيحدد طبيبك الجرعة المناسبة لك.</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الموصى</strong><strong> </strong><strong>بها</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>الصرع</strong></p><p dir="RTL"><strong>البالغون</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">تناول عدد من الكبسولات حسب تعليمات الطبيب. سيقوم الطبيب عادة بزيادة جرعتك تدريجيا. ستتراوح الجرعة الابتدائية بشكل عام بين 300 ملغم و 900 ملغم يوميا. بعد ذلك، قد يتم زيادة الجرعة من قبل الطبيب كحد أقصى إلى 3600 ملغم يوميا. سيخبرك الطبيب بتناولها على 3 جرعات منفصلة، أي واحدة في الصباح، واحدة في وقت الظهيرة و واحدة في المساء.</p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>تبلغ</strong><strong> </strong><strong>أعمارهم</strong><strong> 6 </strong><strong>أعوام</strong><strong> </strong><strong>فما</strong><strong> </strong><strong>فوق</strong></p><p dir="RTL">سيتم تحديد الجرعة التي سيتناولها طفلك من قبل الطبيب حيث يتم حسابها اعتمادا على وزن الطفل. يتم بدء العلاج بجرعة ابتدائية منخفضة التي يتم زيادتها تدريجيا خلال فترة تبلغ تقريبا 3 أيام. تتراوح الجرعة الاعتيادية للسيطرة على الصرع بين 25-35 ملغم لكل كغم من وزن الجسم يوميا. يتم إعطاؤها عادة على 3 جرعات منفصلة، وذلك بتناول الكبسولات يوميا، عادة واحدة في الصباح، واحدة وقت الظهيرة و واحدة في المساء.</p><p dir="RTL">لا يوصى باستعمال <strong>بينتكس</strong><strong><sup>&reg;</sup></strong> للأطفال الذين تقل أعمارهم عن 6 أعوام.</p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>الموصى</strong><strong> </strong><strong>بها</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>الألم</strong><strong> </strong><strong>الناتج</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الاعتلال</strong><strong> </strong><strong>العصبي</strong><strong> </strong><strong>الطرفي</strong></p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">تناول عدد من الكبسولات حسب تعليمات الطبيب. سيقوم الطبيب عادة بزيادة جرعتك تدريجيا. ستتراوح الجرعة الابتدائية بشكل عام بين 300 ملغم و 900 ملغم يوميا. بعد ذلك، قد يتم زيادة الجرعة من قبل الطبيب كحد أقصى إلى 3600 ملغم يوميا. سيخبرك الطبيب بتناولها على 3 جرعات منفصلة، أي واحدة في الصباح، واحدة في وقت الظهيرة و واحدة في المساء.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تعاني</strong><strong> </strong><strong>من</strong><strong> </strong><strong>مشاكل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الكلى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تخضع</strong><strong> </strong><strong>للديلزة</strong><strong> </strong><strong>الدموية</strong></p><p dir="RTL">قد يصف لك الطبيب نظام جرعة و/أو جرعة مختلفة إذا كنت تعاني من مشاكل في الكلى أو كنت تخضع للديلزة الدموية.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كبار</strong><strong> </strong><strong>السن</strong><strong> (</strong><strong>فوق</strong><strong> 65 </strong><strong>عاما</strong><strong>)</strong></p><p dir="RTL">يجب تناول الجرعة المعتادة من <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup>ما لم تكن تعاني من مشاكل في الكلى. قد يصف لك الطبيب نظام جرعة و/أو جرعة مختلفة إذا كنت تعاني من مشاكل في الكلى.</p><p dir="RTL">إذا كنت تشعر بأن تأثير<sup> </sup><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>قوي جدا أو ضعيف جدا، تحدث مع طبيبك أو الصيدلي في أقرب وقت ممكن.</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>الاستعمال</strong></p><p dir="RTL"><strong>بينتكس</strong><strong><sup>&reg; </sup></strong>معد للاستعمال عن طريق الفم. دائما تناول الكبسولات مع كمية<strong><sup> </sup></strong>وفيرة من الماء.</p><p dir="RTL">استمر في تناول <strong>بينتكس</strong><strong><sup>&reg;</sup></strong> إلى أن يخبرك طبيبك بالتوقف.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg; </sup></strong><strong>أكثر</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong></p><p dir="RTL">قد ينتج عن تناول جرعات أعلى من الجرعات الموصى بها زيادة التعرض للآثار الجانبية بما في ذلك فقدان الوعي، الشعور بالدوار، ازدواجية الرؤية، تلعثم الكلام، الشعور بالنعاس و إسهال. إذا تناولت أكثر من الجرعة الموصوفة من قبل الطبيب اتصل مع طبيبك أو اذهب إلى قسم الطوارئ في أقرب مستشفى فورا. واصطحب معك الكبسولات المتبقية مع العبوة والملصق ليتمكن طاقم المستشفى من معرفة الدواء الذي تناولته بسهولة.</p><p dir="RTL">&nbsp;<strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها فور تذكرك ما لم يحن موعد الجرعة التالية. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><sup> </sup></p><p dir="RTL">لا تتوقف عن تناول<sup> </sup><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>ما لم يخبرك الطبيب بذلك. إذا تم التوقف عن العلاج يجب أن يتم بشكل تدريجي خلال أسبوع واحد على الأقل. إذا توقفت عن تناول <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>بشكل مفاجئ أو قبل أن يخبرك الطبيب بذلك، قد يزداد خطر التعرض لنوبات الصرع.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استعمال هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>اتصل</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>فورا</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>عانيت</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>بعد</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong><strong> </strong><strong>حيث</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>خطيرة</strong><strong>:</strong></p><p dir="RTL">تفاعلات جلدية حادة التي تحتاج إلى عناية فورية،&nbsp; تورم الشفاه و الوجه، طفح جلدي واحمرار و/أو تساقط الشعر (قد تكون هذه أعراض لتفاعل تحسسي خطير).</p><p dir="RTL">ألم مستمر في المعدة، الشعور بالغثيان و قيء حيث قد تكون هذه أعراض لالتهاب حاد في البنكرياس.</p><p dir="RTL">مشاكل في التنفس، حيث إذا كانت حادة قد تحتاج إلى عناية طارئة و مكثفة للاستمرار في التنفس بشكل طبيعي.</p><p dir="RTL">قد يسبب جابابنتين تفاعل تحسسي خطير أو مهدد للحياة الذي قد يؤثرعلى الجلد أو أجزاء أخرى من الجسم مثل الكبد أو خلايا الدم. قد تعاني أو قد لا تعاني من الطفح عند حصول هذا النوع من التفاعل. قد يؤدي ذلك إلى إدخالك المستشفى أو التوقف عن تناول<sup> </sup>جابابنتين. اتصل مع طبيبك فورا إذا عانيت من أي من الأعراض التالية:</p><p dir="RTL">- طفح جلدي.</p><p dir="RTL">- شرى.</p><p dir="RTL">- ارتفاع درجة حرارة الجسم.</p><p dir="RTL">- تورم مستمر في الغدد.</p><p dir="RTL">- تورم الشفاه واللسان.</p><p dir="RTL">- اصفرار الجلد أو المنطقة البيضاء في العيون.</p><p dir="RTL">- التعرض للنزيف أو الكدمات على غير المعتاد.</p><p dir="RTL">- الشعور بالتعب أو الضعف الحاد.</p><p dir="RTL">- ألم غير مبرر في العضلات.</p><p dir="RTL">- التهابات متكررة.</p><p dir="RTL"><strong>قد</strong><strong> </strong><strong>تكون</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الأعراض</strong><strong> </strong><strong>العلامات</strong><strong> </strong><strong>الأولية</strong><strong> </strong><strong>لحدوث</strong><strong> </strong><strong>تفاعل</strong><strong> </strong><strong>خطير</strong><strong>. </strong><strong>يجب</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>فحصك</strong><strong> </strong><strong>ليقرر</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كان</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الضروري</strong><strong> </strong><strong>الاستمرار</strong><strong> </strong><strong>بتناول</strong><strong> </strong><strong>جابابنتين</strong><strong>. </strong></p><p dir="RTL">إذا كن تخضع للديلزة الدموية، أخبر طبيبك إذا حصل لديك ألم في العضلات و/أو ضعف.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>تتضمن</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جدا</strong><strong>:</strong> <strong>(</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> 1 </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">التهاب ڤيروسي.</p><p dir="RTL">الشعور بالنعاس، الدوار، فقدان التنسيق.</p><p dir="RTL">الشعور بالتعب، ارتفاع درجة حرارة الجسم.</p><p dir="RTL"><strong>شائعة</strong><strong>: (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">التهاب رئوي، التهابات تنفسية، التهابات الجهاز البولي، التهاب الأذن أو التهابات أخرى.</p><p dir="RTL">انخفاض تعداد خلايا الدم البيضاء.</p><p dir="RTL">قلة الشهية للطعام، زيادة الشهية.</p><p dir="RTL">الغضب اتجاه الآخرين، الارتباك، تغيرات في المزاج، اكتئاب، قلق، عصبية، صعوبة في التفكير.</p><p dir="RTL">تشنجات، حركات غير متوازنة، صعوبة في الكلام، فقدان الذاكرة، رعاش، صعوبة في القدرة على النوم، صداع، حساسية الجلد، فقدان الحس (تنمل)، صعوبة في التنسيق، حركة غير طبيعية في العيون، زيادة، انخفاض أو غياب ردود الأفعال.</p><p dir="RTL">ضبابية الرؤية، ازدواجية الرؤية.</p><p dir="RTL">رنح.</p><p dir="RTL">ارتفاع ضغط الدم، احمرار الوجه أو توسع الأوعية الدموية.</p><p dir="RTL">صعوبة في التنفس، التهاب القصبات، التهاب الحلق، سعال، جفاف الأنف.</p><p dir="RTL">قيء، غثيان، مشاكل في الأسنان، التهاب اللثة، إسهال، ألم في المعدة، عسر الهضم، إمساك، جفاف الفم أو البلعوم، انتفاخ البطن.</p><p dir="RTL">تورم الوجه، التعرض للكدمات، طفح، حكة، حب الشباب.</p><p dir="RTL">ألم في المفاصل، ألم في العضلات، ألم في الظهر، نفضان.</p><p dir="RTL">صعوبة في الانتصاب (عنة).</p><p dir="RTL">تورم الساقين والذراعين، صعوبة في المشي، ضعف، ألم، الشعور بالتعب، أعراض تشبه الإنفلونزا.</p><p dir="RTL">انخفاض عدد خلايا الدم البيضاء، زيادة الوزن.</p><p dir="RTL">إصابات مفاجئة، كسور، كشوط.</p><p dir="RTL">بالإضافة إلى ذلك تم تسجيل حالات من السلوك العدواني والحركات غير المتوازنة بشكل شائع في الدراسات السريرية على الأطفال.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong>: (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 100 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">هياج (حالة مزمنة من الشعور بعدم الراحة والحركات غير المقصودة وبدون هدف).</p><p dir="RTL">تفاعلات تحسسية مثل الشرى.</p><p dir="RTL">قلة الحركة.</p><p dir="RTL">نبضات قلب سريعة.</p><p dir="RTL">صعوبة في البلع.</p><p dir="RTL">التورم الذي قد يشمل الوجه، الجذع والأطراف.</p><p dir="RTL">نتائج فحص دم غير طبيعية التي تدل على وجود مشاكل في الكبد.</p><p dir="RTL">ضعف القدرة العقلية.</p><p dir="RTL">التعرض للسقوط.</p><p dir="RTL">ارتفاع مستويات الجلوكوز في الدم (غالبا يتم ملاحظته عند المرضى الذين يعانون من داء السكري).</p><p dir="RTL"><strong>نادرة</strong><strong>: (</strong><strong>قد</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> 1 </strong><strong>أو</strong><strong> </strong><strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>كل</strong><strong> 1000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">انخفاض مستويات الجلوكوز في الدم (غالبا يتم ملاحظته عند المرضى الذين يعانون من داء السكري).</p><p dir="RTL">فقدان الوعي.</p><p dir="RTL">مشاكل في التنفس، تنفس ضحل (قصور في التنفس).</p><p dir="RTL"><strong>تم</strong><strong> </strong><strong>تسجيل</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>التالية</strong><strong> </strong><strong>بعد</strong><strong> </strong><strong>تسويق</strong><strong> </strong><strong>جابابنتين</strong><strong>:</strong></p><p dir="RTL">انخفاض الصفيحات الدموية (خلايا تخثر الدم).</p><p dir="RTL">أفكار انتحارية، هلوسات.</p><p dir="RTL">مشاكل الحركات غير الطبيعية مثل الالتواء، الحركات غير المتوازنة والتيبس.</p><p dir="RTL">رنين في الأذن.</p><p dir="RTL">مجموعة من الآثار الجانبية تحدث معا والتي قد تتضمن تورم العقد الليمفاوية (كتل منعزلة صغيرة مرتفعة تحت سطح الجلد)، ارتفاع درجة حرارة الجسم، طفح، والتهاب الكبد.</p><p dir="RTL">اصفرار الجلد والمنطقة البيضاء في العيون (يرقان)، التهاب الكبد.</p><p dir="RTL">قصور حاد في وظيفة الكلى، سلس البول.</p><p dir="RTL">زيادة أنسجة الثدي، تضخم الثدي.</p><p dir="RTL">آثار جانبية تتبع التوقف المفاجئ عن تناول جابابنتين (قلق، صعوبة في القدرة على النوم، غثيان، ألم، تعرق، ألم في الصدر).</p><p dir="RTL">تحلل الألياف العضلية (تحلل العضلات المخططة).</p><p dir="RTL">تغير في نتائج فحوصات الدم (زيادة مستوى كرياتين كاينيز في الدم).</p><p dir="RTL">مشاكل في الأداء الجنسي بما في ذلك عدم القدرة على الوصول إلى رعشة الجماع، تأخر القذف.</p><p dir="RTL">انخفاض مستوى الصوديوم في الدم.</p><p dir="RTL">فرط التحسس (تفاعل تحسسي خطير، من المحتمل أن يكون مهدد للحياة ويتضمن صعوبة التنفس، تورم الشفاه، الحلق، واللسان، وانخفاض ضغط الدم الذي يحتاج إلى علاج طارئ).</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>حصل</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية،</strong><strong> </strong><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong>. </strong><strong>وهذا</strong><strong> </strong><strong>يشمل</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>مذكورة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>النشرة</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستعمل كبسولات <strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>بعد تاريخ انتهاء الصلاحية (EXP) المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong>كبسولات: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>كبسولات</strong><strong>:</strong></p><p dir="RTL">المادة الفعالة هي جابابنتين.</p><p dir="RTL">المكونات الأخرى هي لاكتوز أحادي الهيدرات، نشا الذرة، تلك، ستيرات المغنيسيوم.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> 300 </strong><strong>ملغم</strong><strong> </strong><strong>كبسولات</strong><strong>:</strong> هي كبسولات جيلاتينية صلبة، حجم 0 ذات جسم رملي اللون مطبوع عليه &ldquo;CAP02&rdquo; و غطاء برتقالي اللون مائل إلى البني بدون طباعة، معبأة في أشرطة بي ڤي سي/ بي ڤي دي سي/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 كبسولة جيلاتينية صلبة (10 كبسولات/شريط، 3 أشرطة / عبوة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بينتكس</strong><strong><sup>&reg;</sup></strong><strong> 400 </strong><strong>ملغم</strong><strong> </strong><strong>كبسولات</strong><strong>:</strong> هي كبسولات جيلاتينية صلبة، حجم 0 ممدودة الشكل، ذات جسم عاجي اللون غير شفاف، مطبوع عليه &ldquo;CAP03&rdquo; وغطاء أزرق غير شفاف بدون طباعة، معبأة في أشرطة بي ڤي سي/ بي ڤي دي سي/ألومنيوم، معدة للاستعمال عن طريق الفم.</p><p dir="RTL"><strong>حجم</strong><strong> </strong><strong>العبوة</strong><strong>:</strong> 30 كبسولة جيلاتينية صلبة (10 كبسولات/شريط، 3 أشرطة / عبوة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية.</p><p dir="RTL">الهاتف:&nbsp; 00966920003288&nbsp;</p><p dir="RTL">فاكس: 00966126358138</p><p dir="RTL">جوال: 00966555786968&nbsp;</p><p dir="RTL">ص.ب: 42512 &ndash; جدة 21551</p><p dir="RTL">البريد الإلكتروني: MD.admin@axantia.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2024  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pentix® 300 mg Hard Gelatin Capsules.
Pentix® 400 mg Hard Gelatin Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pentix® 300 mg: Each hard gelatin capsules contains 300 mg gabapentin.
Pentix® 400 mg: Each hard gelatin capsules contains 400 mg gabapentin.

For a full list of excipients: see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatin Capsules.

Pentix® 300mg capsules: Size zero, hard gelatin capsule, with beige color body printed with "CAP02" and brownish orange color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.
Pentix® 400mg capsules: Size zero elongated, hard gelatin capsule, with Ivory opaque color body printed with "CAP03" and blue opaque color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Epilepsy</u></p><p><strong>Pentix<sup>&reg; </sup></strong>is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and children aged 6 years and above (see section 5.1).</p><p><strong>Pentix<sup>&reg; </sup></strong>is indicated as monotherapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above.</p><p><u>Treatment of peripheral neuropathic pain</u></p><p><strong>Pentix<sup>&reg; </sup></strong>is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p>For all indications a titration scheme for the initiation of therapy is described in Table 1, which is recommended for adults and adolescents aged 12 years and above. Dosing instructions for children under 12 years of age are provided under a separate sub-heading later in this section.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DOSING CHART &ndash; INITIAL TITRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td></tr><tr><td style="vertical-align:top"><p>300 mg once a day</p></td><td style="vertical-align:top"><p>300 mg two times a day</p></td><td style="vertical-align:top"><p>300 mg three times a day</p></td></tr></tbody></table><p><strong><u>Discontinuation of gabapentin</u></strong></p><p>In accordance with current clinical practice, if gabapentin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication.</p><p><strong><u>Epilepsy</u></strong></p><p>Epilepsy typically requires long-term therapy. Dosage is determined by the treating physician according to individual tolerance and efficacy.</p><p><em>Adults and adolescents</em></p><p>In clinical trials, the effective dosing range was 900 to 3600 mg/day. Therapy may be initiated by titrating the dose as described in Table 1 or by administering 300 mg three times a day (TID) on Day 1. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration of gabapentin dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks. Dosages up to 4800 mg/day have been well tolerated in long-term open-label clinical studies. The total daily dose should be divided in three single doses, the maximum time interval between the doses should not exceed 12 hours to prevent breakthrough convulsions.</p><p><em>Children aged 6 years and above</em></p><p>The starting dose should range from 10 to 15 mg/kg/day and the effective dose is reached by upward titration over a period of approximately three days. The effective dose of gabapentin in children aged 6 years and older is 25 to 35 mg/kg/day. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The total daily dose should be divided in three single doses, the maximum time interval between doses should not exceed 12 hours.</p><p>It is not necessary to monitor gabapentin plasma concentrations to optimize gabapentin therapy. Further, gabapentin may be used in combination with other antiepileptic medicinal products without concern for alteration of the plasma concentrations of gabapentin or serum concentrations of other antiepileptic medicinal products.</p><p><strong><u>Peripheral neuropathic pain</u></strong></p><p><em>Adults</em></p><p>The therapy may be initiated by titrating the dose as described in Table 1. Alternatively, the starting dose is 900 mg/day given as three equally divided doses. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration of gabapentin dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks.</p><p>In the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than 5 months. If a patient requires dosing longer than 5 months for the treatment of peripheral neuropathic pain, the treating physician should assess the patient&#39;s clinical status and determine the need for additional therapy.</p><p><strong><u>Instruction for all areas of indication</u></strong></p><p>In patients with poor general health, i.e., low body weight, after organ transplantation etc., the dose should be titrated more slowly, either by using smaller dosage strengths or longer intervals between dosage increases.</p><p><strong><u>Elderly (over 65 years of age)</u></strong></p><p>Elderly patients may require dosage adjustment because of declining renal function with age (see Table 2). Somnolence, peripheral oedema and asthenia may be more frequent in elderly patients.</p><p><strong><u>Renal impairment</u></strong></p><p>Dosage adjustment is recommended in patients with compromised renal function as described in Table 2 and/or those undergoing haemodialysis. Gabapentin 100 mg capsules can be used to follow dosing recommendations for patients with renal insufficiency.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table 2</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>DOSAGE OF GABAPENTIN IN ADULTS BASED ON RENAL FUNCTION</strong></p></td></tr><tr><td style="vertical-align:top"><p>Creatinine Clearance (mL/min)</p></td><td style="vertical-align:top"><p>Total Daily Dose<sup>a</sup>&nbsp;(mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;80</p></td><td style="vertical-align:top"><p>900-3600</p></td></tr><tr><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>600-1800</p></td></tr><tr><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>300-900</p></td></tr><tr><td style="vertical-align:top"><p>15-29</p></td><td style="vertical-align:top"><p>150<sup>b</sup>-600</p></td></tr><tr><td style="vertical-align:top"><p>&lt;15<sup>c</sup></p></td><td style="vertical-align:top"><p>150<sup>b</sup>-300</p></td></tr></tbody></table><p><sup>a&nbsp;</sup>Total daily dose should be administered as three divided doses. Reduced dosages are for patients with renal impairment (creatinine clearance &lt; 79 mL/min).</p><p><sup>b</sup>&nbsp;The 150 mg daily dose to be administered as 300 mg every other day.</p><p><sup>c&nbsp;</sup>For patients with creatinine clearance &lt;15 mL/min, the daily dose should be reduced in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 mL/min should receive one-half the daily dose that patients with a creatinine clearance of 15 mL/min receive).</p><p><strong><u>Use in patients undergoing haemodialysis</u></strong></p><p>For anuric patients undergoing haemodialysis who have never received gabapentin, a loading dose of 300 to 400 mg, then 200 to 300 mg of gabapentin following each 4 hours of haemodialysis, is recommended. On dialysis-free days, there should be no treatment with gabapentin.</p><p>For renally impaired patients undergoing haemodialysis, the maintenance dose of gabapentin should be based on the dosing recommendations found in Table 2. In addition to the maintenance dose, an additional 200 to 300 mg dose following each 4-hour haemodialysis treatment is recommended.</p><p><u>Method of administration</u></p><p>For oral use.</p><p>Gabapentin can be given with or without food and should be swallowed whole with sufficient fluid-intake (e.g. a glass of water).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)</u></p><p>Severe, life-threatening, systemic hypersensitivity reactions such as Drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking antiepileptic drugs including gabapentin (see section 4.8).</p><p>It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Gabapentin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p><p><u>Anaphylaxis</u></p><p>Gabapentin can cause anaphylaxis. Signs and symptoms in reported cases have included difficulty breathing, swelling of the lips, throat, and tongue, and hypotension requiring emergency treatment. Patients should be instructed to discontinue gabapentin and seek immediate medical care should they experience signs or symptoms of anaphylaxis (see section 4.8).</p><p><u>Suicidal ideation and behaviour</u></p><p>Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known. Cases of suicidal ideation and behaviour have been observed in patients treated with gabapentin in the post-marketing experience (see section 4.8).</p><p>Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. Patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Discontinuation of gabapentin treatment should be considered in case of suicidal ideation and behaviour.</p><p><u>Acute pancreatitis</u></p><p>If a patient develops acute pancreatitis under treatment with gabapentin, discontinuation of gabapentin should be considered (see section 4.8).</p><p><u>Seizures</u></p><p>Although there is no evidence of rebound seizures with gabapentin, abrupt withdrawal of anticonvulsants in epileptic patients may precipitate status epilepticus (see section 4.2).</p><p>As with other antiepileptic medicinal products, some patients may experience an increase in seizure frequency or the onset of new types of seizures with gabapentin.</p><p>As with other anti-epileptics, attempts to withdraw concomitant anti-epileptics in treatment refractive patients on more than one anti-epileptic, in order to reach gabapentin monotherapy have a low success rate.</p><p>Gabapentin is not considered effective against primary generalized seizures such as absences and may aggravate these seizures in some patients. Therefore, gabapentin should be used with caution in patients with mixed seizures including absences.</p><p>Gabapentin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall). There have also been post-marketing reports of confusion, loss of consciousness and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication.</p><p><u>Concomitant use with opioids and other CNS depressants </u></p><p>Patients who require concomitant treatment with central nervous system (CNS) depressants, including opioids, should be carefully observed for signs of CNS depression, such as somnolence, sedation, and respiratory depression. Patients who use gabapentin and morphine concomitantly may experience increases in gabapentin concentrations. The dose of gabapentin, or concomitant treatment with CNS depressants including opioids, should be reduced appropriately (see section 4.5).</p><p>Caution is advised when prescribing gabapentin concomitantly with opioids due to risk of CNS depression. In a population-based, observational, nested case-control study of opioid users, co-prescription of opioids and gabapentin was associated with an increased risk for opioid-related death compared to opioid prescription use alone (adjusted odds ratio [aOR], 1.49 [95% CI, 1.18 to 1.88, p&lt;0.001]).</p><p><u>Respiratory depression</u></p><p>Gabapentin has been associated with severe respiratory depression. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use of CNS depressants and the elderly might be at higher risk of experiencing this severe adverse reaction. Dose adjustments might be necessary in these patients.</p><p><u>Elderly (over 65 years of age)</u></p><p>No systematic studies in patients 65 years or older have been conducted with gabapentin. In one double blind study in patients with neuropathic pain, somnolence, peripheral oedema and asthenia occurred in a somewhat higher percentage in patients aged 65 years or above, than in younger patients. Apart from these findings, clinical investigations in this age group do not indicate an adverse event profile different from that observed in younger patients.</p><p><u>Paediatric population</u></p><p>The effects of long-term (greater than 36 weeks) gabapentin therapy on learning, intelligence, and development in children and adolescents have not been adequately studied. The benefits of prolonged therapy must therefore be weighed against the potential risks of such therapy.</p><p><u>Abuse and dependence</u></p><p>Cases of abuse and dependence have been reported in the post-marketing database. Carefully evaluate patients for a history of drug abuse and observe them for possible signs of gabapentin abuse e.g. drug-seeking behaviour, dose escalation, development of tolerance.</p><p><u>Laboratory tests</u></p><p>False positive readings may be obtained in the semi-quantitative determination of total urine protein by dipstick tests. It is therefore recommended to verify such a positive dipstick test result by methods based on a different analytical principle such as the Biuret method, turbidimetric or dye-binding methods, or to use these alternative methods from the beginning.</p><p><u>Excipients with known effect</u></p><p><strong>Pentix<sup>&reg; </sup></strong>capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are spontaneous and literature case reports of respiratory depression, sedation, and death associated with gabapentin when co-administered with CNS depressants, including opioids. In some of these reports, the authors considered the combination of gabapentin with opioids to be a particular concern in frail patients, in the elderly, in patients with serious underlying respiratory disease, with polypharmacy, and in those with substance abuse disorders.</p><p>In a study involving healthy volunteers (N=12), when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg gabapentin capsule, mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine. Therefore, patients who require concomitant treatment with opioids should be carefully observed for signs of CNS depression, such as somnolence, sedation and respiratory depression and the dose of gabapentin or opioid should be reduced appropriately.</p><p>No interaction between gabapentin and phenobarbital, phenytoin, valproic acid, or carbamazepine has been observed.</p><p>Gabapentin steady-state pharmacokinetics are similar for healthy subjects and patients with epilepsy receiving these antiepileptic agents.</p><p>Co-administration of gabapentin with oral contraceptives containing norethindrone and/or ethinyl estradiol, does not influence the steady-state pharmacokinetics of either component.</p><p>Co-administration of gabapentin with antacids containing aluminium and magnesium, reduces gabapentin bioavailability up to 24%. It is recommended that gabapentin be taken at the earliest two hours following antacid administration.</p><p>Renal excretion of gabapentin is unaltered by probenecid.</p><p>A slight decrease in renal excretion of gabapentin that is observed when it is co-administered with cimetidine is not expected to be of clinical importance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>Risk related to epilepsy and antiepileptic medicinal products in general</em></p><p>The risk of birth defects is increased by a factor of 2-3 in the offspring of mothers treated with an antiepileptic medicinal product. Most frequently reported are cleft lip, cardiovascular malformations and neural tube defects. Multiple antiepileptic drug therapy may be associated with a higher risk of congenital malformations than monotherapy, therefore it is important that monotherapy is practised whenever possible. Specialist advice should be given to women who are likely to become pregnant or who are of childbearing potential and the need for antiepileptic treatment should be reviewed when a woman is planning to become pregnant. No sudden discontinuation of antiepileptic therapy should be undertaken as this may lead to breakthrough seizures, which could have serious consequences for both mother and child. Developmental delay in children of mothers with epilepsy has been observed rarely. It is not possible to differentiate if the developmental delay is caused by genetic, social factors, maternal epilepsy or the antiepileptic therapy.</p><p><em>Risk related to gabapentin</em></p><p>Gabapentin crosses the human placenta.</p><p>There are no or limited amount of data from the use of gabapentin in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Gabapentin should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>No definite conclusion can be made as to whether gabapentin is causally associated with an increased risk of congenital malformations when taken during pregnancy, because of epilepsy itself and the presence of concomitant antiepileptic medicinal products during each reported pregnancy.</p><p><u>Breast-feeding</u></p><p>Gabapentin is excreted in human milk. Because the effect on the breast-fed infant is unknown, caution should be exercised when gabapentin is administered to a breast-feeding mother. Gabapentin should be used in breast-feeding mothers only if the benefits clearly outweigh the risks.</p><p><u>Fertility</u></p><p>There is no effect on fertility in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gabapentin may have minor or moderate influence on the ability to drive and use machines. Gabapentin acts on the central nervous system and may cause drowsiness, dizziness or other related symptoms. Even, if they were only of mild or moderate degree, these undesirable effects could be potentially dangerous in patients driving or operating machinery. This is especially true at the beginning of the treatment and after increase in dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions observed during clinical studies conducted in epilepsy (adjunctive and monotherapy) and neuropathic pain have been provided in a single list below by class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to&lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Where an adverse reaction was seen at different frequencies in clinical studies, it was assigned to the highest frequency reported.</p><p>Additional reactions reported from post-marketing experience are included as frequency Not known (cannot be estimated from the available data) in italics in the list below.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>viral infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pneumonia, respiratory infection, urinary tract infection, infection, otitis media</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Thrombocytopenia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>allergic reactions (e.g. urticaria<em>)</em></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>hypersensitivity syndrome (a systemic reaction with a variable presentation that can include fever, rash, hepatitis, lymphadenopathy, eosinophilia, and sometimes other signs and symptoms), anaphylaxis (see section 4.4)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>anorexia, increased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hyperglycaemia (most often observed in patients with diabetes)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>hypoglycaemia (most often observed in patients with diabetes)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>hyponatraemia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hostility, confusion and emotional lability, depression, anxiety, nervousness, thinking abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>agitation</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>suicidal ideation, hallucinations</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>somnolence, dizziness, ataxia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>convulsions, hyperkinesias, dysarthria, amnesia, tremor, insomnia, headache, sensations such as paresthesia, hypaesthesia, coordination abnormal, nystagmus, increased, decreased, or absent reflexes</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypokinesia, mental impairment</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>loss of consciousness</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>other movement disorders (e.g. choreoathetosis, dyskinesia, dystonia)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>visual disturbances such as amblyopia, diplopia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>tinnitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>palpitations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hypertension, vasodilatation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dyspnoea, bronchitis, pharyngitis, cough, rhinitis</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>respiratory depression</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vomiting, nausea, dental abnormalities, gingivitis, diarrhea, abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>dysphagia</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>pancreatitis</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>hepatitis, jaundice</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>facial oedema, purpura most often described as bruises resulting from physical trauma, rash, pruritus, acne</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Stevens-Johnson syndrome, angioedema, erythema multiforme, alopecia, drug rash with eosinophilia and systemic symptoms (see section 4.4)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>arthralgia, myalgia, back pain, twitching</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>rhabdomyolysis, myoclonus</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorder</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>acute renal failure, incontinence</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>impotence</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>breast hypertrophy, gynaecomastia, sexual dysfunction (including changes in libido, ejaculation disorders and anorgasmia)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>fatigue, fever</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>peripheral oedema, abnormal gait, asthenia, pain, malaise, flu syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>generalized oedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>withdrawal reactions (mostly anxiety, insomnia, nausea, pains, sweating), chest pain. Sudden unexplained deaths have been reported where a causal relationship to treatment with gabapentin has not been established.</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>WBC (white blood cell count) decreased, weight gain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>elevated liver function tests SGOT (AST), SGPT (ALT) and bilirubin</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>blood creatine phosphokinase increased</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>accidental injury, fracture, abrasion</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>fall</p></td></tr></tbody></table><p>Under treatment with gabapentin cases of acute pancreatitis were reported. Causality with gabapentin is unclear (see section 4.4).</p><p>In patients on haemodialysis due to end-stage renal failure, myopathy with elevated creatine kinase levels has been reported.</p><p>Respiratory tract infections, otitis media, convulsions and bronchitis were reported only in clinical studies in children. Additionally, in clinical studies in children, aggressive behaviour and hyperkinesias were reported commonly.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect</strong>(<strong>s</strong>)<strong>:</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute, life-threatening toxicity has not been observed with gabapentin overdoses of up to 49 g. Symptoms of the overdoses included dizziness, double vision, slurred speech, drowsiness, loss of consciousness, lethargy and mild diarrhea. All patients recovered fully with supportive care. Reduced absorption of gabapentin at higher doses may limit drug absorption at the time of overdosing and, hence, minimize toxicity from overdoses.</p><p>Overdoses of gabapentin, particularly in combination with other CNS depressant medications, may result in coma.</p><p>Although gabapentin can be removed by haemodialysis, based on prior experience it is usually not required. However, in patients with severe renal impairment, haemodialysis may be indicated.</p><p>An oral lethal dose of gabapentin was not identified in mice and rats given doses as high as 8000 mg/kg. Signs of acute toxicity in animals included ataxia, laboured breathing, ptosis, hypoactivity, or excitation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic groups: Other antiepileptics ATC code: N03AX12</p><p><u>Mechanism of action</u></p><p>Gabapentin readily enters the brain and prevents seizures in a number of animal models of epilepsy. Gabapentin does not possess affinity for either GABAA or GABAB receptor nor does it alter the metabolism of GABA. It does not bind to other neurotransmitter receptors of the brain and does not interact with sodium channels. Gabapentin binds with high affinity to the &alpha;2&delta; (alpha-2-delta) subunit of voltage-gated calcium channels and it is proposed that binding to the &alpha;2&delta; subunit may be involved in gabapentin&#39;s anti-seizure effects in animals. Broad panel screening does not suggest any other drug targets other than &alpha;2&delta;.</p><p>Evidence from several pre-clinical models inform that the pharmacological activity of gabapentin may be mediated via binding to &alpha;2&delta; through a reduction in release of excitatory neurotransmitters in regions of the central nervous system. Such activity may underlie gabapentin&#39;s anti-seizure activity. The relevance of these actions of gabapentin to the anticonvulsant effects in humans remains to be established.</p><p>Gabapentin also displays efficacy in several pre-clinical animal pain models. Specific binding of gabapentin to the &alpha;2&delta; subunit is proposed to result in several different actions that may be responsible for analgesic activity in animal models. The analgesic activities of gabapentin may occur in the spinal cord as well as at higher brain centers through interactions with descending pain inhibitory pathways. The relevance of these pre-clinical properties to clinical action in humans is unknown.</p><p><u>Clinical efficacy and safety</u></p><p>A clinical trial of adjunctive treatment of partial seizures in paediatric subjects ranging in age from 3 to 12 years, showed a numerical but not statistically significant difference in the 50% responder rate in favour of the gabapentin group compared to placebo. Additional post-hoc analyses of the responder rates by age did not reveal a statistically significant effect of age, either as a continuous or dichotomous variable (age groups 3-5 and 6-12 years).</p><p>The data from this additional post-hoc analysis are summarised in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Response (&ge; 50% Improved) by Treatment and Age MITT* Population</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age Category</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Gabapentin</p></td><td style="vertical-align:top"><p>P-Value</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 6 Years Old</p></td><td style="vertical-align:top"><p>4/21 (19.0%)</p></td><td style="vertical-align:top"><p>4/17 (23.5%)</p></td><td style="vertical-align:top"><p>0.7362</p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 Years Old</p></td><td style="vertical-align:top"><p>17/99 (17.2%)</p></td><td style="vertical-align:top"><p>20/96 (20.8%)</p></td><td style="vertical-align:top"><p>0.5144</p></td></tr></tbody></table><p>*The modified intent to treat population was defined as all patients randomised to study medication who also had evaluable seizure diaries available for 28 days during both the baseline and double-blind phases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration, peak plasma gabapentin concentrations are observed within 2 to 3 hours. Gabapentin bioavailability (fraction of dose absorbed) tends to decrease with increasing dose. Absolute bioavailability of a 300 mg capsule is approximately 60%. Food, including a high-fat diet, has no clinically significant effect on gabapentin pharmacokinetics.</p><p>Gabapentin pharmacokinetics are not affected by repeated administration. Although plasma gabapentin concentrations were generally between 2 &mu;g/mL and 20 &mu;g/mL in clinical studies, such concentrations were not predictive of safety or efficacy. Pharmacokinetic parameters are given in Table 3.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 3</strong></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>SUMMARY OF GABAPENTIN MEAN (%CV) STEADY-STATE PHARMACOKINETIC PARAMETERS FOLLOWING EVERY EIGHT HOURS ADMINISTRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pharmacokinetic parameter</p></td><td colspan="2" style="vertical-align:top"><p>300 mg</p><p>(N=7)</p></td><td colspan="2" style="vertical-align:top"><p>400 mg</p><p>(N=14)</p></td><td colspan="2" style="vertical-align:top"><p>800 mg</p><p>(N=14)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub>&nbsp;(&mu;g/mL)</p></td><td style="vertical-align:top"><p>4.02</p></td><td style="vertical-align:top"><p>(24)</p></td><td style="vertical-align:top"><p>5.74</p></td><td style="vertical-align:top"><p>(38)</p></td><td style="vertical-align:top"><p>8.71</p></td><td style="vertical-align:top"><p>(29)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>max</sub>&nbsp;(hr)</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>(18)</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>(54)</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>(76)</p></td></tr><tr><td style="vertical-align:top"><p>T1/2 (hr)</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>(12)</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>(89)</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>(41)</p></td></tr><tr><td style="vertical-align:top"><p>AUC (0-8) &mu;g&bull;hr/mL)</p></td><td style="vertical-align:top"><p>24.8</p></td><td style="vertical-align:top"><p>(24)</p></td><td style="vertical-align:top"><p>34.5</p></td><td style="vertical-align:top"><p>(34)</p></td><td style="vertical-align:top"><p>51.4</p></td><td style="vertical-align:top"><p>(27)</p></td></tr><tr><td style="vertical-align:top"><p>Ae% (%)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>47.2</p></td><td style="vertical-align:top"><p>(25)</p></td><td style="vertical-align:top"><p>34.4</p></td><td style="vertical-align:top"><p>(37)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>C<sub>max</sub>&nbsp;= Maximum steady state plasma concentration</p><p>t<sub>max</sub>&nbsp;= Time for C<sub>max</sub></p><p>T1/2 = Elimination half-life</p><p>AUC(0-8) = Steady state area under plasma concentration-time curve from time 0 to 8 hours postdose</p><p>Ae% = Percent of dose excreted unchanged into the urine from time 0 to 8 hours postdose</p><p>NA = Not available</p></td></tr></tbody></table><p><u>Distribution</u></p><p>Gabapentin is not bound to plasma proteins and has a volume of distribution equal to 57.7 litres. In patients with epilepsy, gabapentin concentrations in cerebrospinal fluid (CSF) are approximately 20% of corresponding steady-state trough plasma concentrations. Gabapentin is present in the breast milk of breast-feeding women.</p><p><u>Biotransformation</u></p><p>There is no evidence of gabapentin metabolism in humans. Gabapentin does not induce hepatic mixed function oxidase enzymes responsible for drug metabolism.</p><p><u>Elimination</u></p><p>Gabapentin is eliminated unchanged solely by renal excretion. The elimination half-life of gabapentin is independent of dose and averages 5 to 7 hours.</p><p>In elderly patients, and in patients with impaired renal function, gabapentin plasma clearance is reduced. Gabapentin elimination-rate constant, plasma clearance, and renal clearance are directly proportional to creatinine clearance.</p><p>Gabapentin is removed from plasma by haemodialysis. Dosage adjustment in patients with compromised renal function or undergoing haemodialysis is recommended (see section 4.2).</p><p>Gabapentin pharmacokinetics in children were determined in 50 healthy subjects between the ages of 1 month and 12 years. In general, plasma gabapentin concentrations in children &gt; 5 years of age are similar to those in adults when dosed on a mg/kg basis.</p><p>In a pharmacokinetic study in 24 healthy paediatric subjects aged between 1 month and 48 months, an approximately 30% lower exposure (AUC), lower Cmax and higher clearance per body weight have been observed in comparison to available reported data in children older than 5 years.</p><p><u>Linearity/non-linearity</u></p><p>Gabapentin bioavailability (fraction of dose absorbed) decreases with increasing dose which imparts non-linearity to pharmacokinetic parameters which include the bioavailability parameter (F) e.g. Ae%, CL/F, Vd/F. Elimination pharmacokinetics (pharmacokinetic parameters which do not include F such as CLr and T1/2), are best described by linear pharmacokinetics. Steady state plasma gabapentin concentrations are predictable from single-dose data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis</u></p><p>Gabapentin was given in the diet to mice at 200, 600, and 2000 mg/kg/day and to rats at 250, 1000, and 2000 mg/kg/day for two years. A statistically significant increase in the incidence of pancreatic acinar cell tumors was found only in male rats at the highest dose. Peak plasma drug concentrations in rats at 2000 mg/kg/day are 10 times higher than plasma concentrations in humans given 3600 mg/day. The pancreatic acinar cell tumors in male rats are low-grade malignancies, did not affect survival, did not metastasize or invade surrounding tissue, and were similar to those seen in concurrent controls. The relevance of these pancreatic acinar cell tumors in male rats to carcinogenic risk in humans is unclear.</p><p><u>Mutagenesis</u></p><p>Gabapentin demonstrated no genotoxic potential. It was not mutagenic&nbsp;<em>in vitro</em>&nbsp;in standard assays using bacterial or mammalian cells. Gabapentin did not induce structural chromosome aberrations in mammalian cells&nbsp;<em>in vitro</em>&nbsp;or&nbsp;<em>in vivo</em>, and did not induce micronucleus formation in the bone marrow of hamsters.</p><p><u>Impairment of fertility</u></p><p>No adverse effects on fertility or reproduction were observed in rats at doses up to 2000 mg/kg (approximately five times the maximum daily human dose on a mg/m<sup>2</sup>&nbsp;of body surface area basis).</p><p><u>Teratogenesis</u></p><p>Gabapentin did not increase the incidence of malformations, compared to controls, in the offspring of mice, rats, or rabbits at doses up to 50, 30 and 25 times respectively, the daily human dose of 3600 mg, (four, five or eight times, respectively, the human daily dose on a mg/m2 basis).</p><p>Gabapentin induced delayed ossification in the skull, vertebrae, forelimbs, and hindlimbs in rodents, indicative of fetal growth retardation. These effects occurred when pregnant mice received oral doses of 1000 or 3000 mg/kg/day during organogenesis and in rats given 2000 mg/kg prior to and during mating and throughout gestation. These doses are approximately 1 to 5 times the human dose of 3600 mg on a mg/m2 basis.</p><p>No effects were observed in pregnant mice given 500 mg/kg/day (approximately 1/2 of the daily human dose on a mg/m2 basis).</p><p>An increased incidence of hydroureter and/or hydronephrosis was observed in rats given 2000 mg/kg/day in a fertility and general reproduction study, 1500 mg/kg/day in a teratology study, and 500, 1000, and 2000 mg/kg/day in a perinatal and postnatal study. The significance of these findings is unknown, but they have been associated with delayed development. These doses are also approximately 1 to 5 times the human dose of 3600 mg on a mg/m2 basis.</p><p>In a teratology study in rabbits, an increased incidence of post-implantation fetal loss, occurred in pregnant rabbits given 60, 300, and 1500 mg/kg/day during organogenesis. These doses are approximately 0.3 to 8 times the daily human dose of 3600 mg on a mg/m2 basis. The margins of safety are insufficient to rule out the risk of these effects in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, Maize starch, Talc, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pentix<sup>&reg;</sup> 300mg capsules: </strong>Size zero, hard gelatin capsule, with beige color body printed with &quot;CAP02&quot; and brownish orange color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 Hard Gelatin Capsules (10 Capsule/blister, 3 blisters/pack).</p><p><strong>Pentix<sup>&reg;</sup> 400mg capsules: </strong>Size zero elongated, hard gelatin capsule, with Ivory opaque color body printed with &quot;CAP03&quot; and blue opaque color blank cap, presented in PVC/PVDC/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 30 Hard Gelatin Capsules (10 Capsule/blister, 3 blisters/pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma-KSA.
Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551
E-mail: MD.admin@Axantia.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>